• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Halozyme-Genentech breast cancer pivotal meets endpoint

September 13, 2019 By Danielle Kirsh

halozyme-logoHalozyme Therapeutics today announced positive endpoint results from its phase III intravenous chemotherapy trial.

Genentech’s FeDeriCa study used Halozyme’s Enhanze drug-delivery technology for subcutaneous administration of a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin), in combination with intravenous chemotherapy. The results showed non-inferior levels of Perjeta in the blood compared to standard IV infusion with Herceptin in chemotherapy patients with HER2-positive early breast cancer.

“The results of the phase III FeDeriCa study represent an important development for our Enhanze drug-delivery technology,” president & CEO Helen Torley said in a news release. “This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our Enhanze technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option.”

A fixed-dose combination of Perjeta and Herceptin through subcutaneous administration takes eight minutes for the initial loading dose and about five minutes for each subsequent maintenance dose, according to Halozyne. Standard IV formulations of the drug combination take about 150 minutes for IV administration and 60-150 minutes for subsequent maintenance doses.

The study also showed the safety profile of the drug combination was consistent with the safety profile of IV-administered Perjeta and Herceptin.

Filed Under: Clinical Trials, Drug-Device Combinations, Oncology Tagged With: Genzyme, Halozyme Therapeutics

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS